Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tucidinostat · CS-055, HBI-8000

Small molecule · Inhibitor of histone deacetylase 1 (HDAC1), histone deacetylase 2 (HDAC2) and histone deacetylase 3 (HDAC3) · developed by Chipscreen Biosciences

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Tucidinostat?

Tucidinostat is an orally bioavailable benzamide-type histone deacetylase (HDAC) inhibitor targeting HDAC isoenzymes 1, 2, 3, and 10. It increases histone acetylation and inhibits PI3K/Akt and MAPK/Ras signaling, leading to cell cycle arrest and apoptosis in tumor cells. It is studied in non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CS-055, HBI-8000, Chidamide
Drug type
Small molecule
Targets
histone deacetylase 1 (HDAC1), histone deacetylase 2 (HDAC2), histone deacetylase 3 (HDAC3), histone deacetylase 10 (HDAC10)
Mechanism
Inhibitor of histone deacetylase 1 (HDAC1), histone deacetylase 2 (HDAC2) and histone deacetylase 3 (HDAC3)
Pathways
PI3K/Akt, MAPK/Ras, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Chipscreen Biosciences, Ltd.
In trials of
AAPG
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
87CIC980Y0

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05186012 Phase 1/2 NHL, Adult Unknown AAPG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NHL, Adult

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.